Stockreport

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 [Yahoo! Finance]

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF antibody, in combination with durvalumab and chemotherapy in resectable NSCLC; these results will be presented at the Clinical Trials Plenary Session at the AACR Annual [Read more]